This content is from:APP亚博娱乐

Zafgen Raises $33M In VC Funding

Pharmaceutical company Zafgen has secured $33 million in Series C venture funding.

    Pharmaceutical companyZafgenhas secured $33 million in Series C venture funding. The financing was led by an existing investor syndicate, which includesAtlas VentureandThird Rock Ventures.

    The company intends to use part of the proceeds to advance an obesity drug into Phase 2 clinical studies. Cambridge, Massachusetts-based Zafgen’s technology is designed to target imbalances in fat metabolism.

    Click here for the release fromZafgen.

    Related Content